Stock Scorer

Eton Pharmaceuticals, Inc. (ETON) · Insider trading

What Eton Pharmaceuticals's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.

Bought, 12 months
$0
0 insiders, 0 trades
Sold, 12 months
$25.41M
5 insiders, 0% under a plan
Net, 12 months
−$25.41M
bought less sold
Latest filing
2026-10-06
filings read to 2026-10-19

Bought and sold at the market, by month

Two years. Purchases above the line, sales below, in dollars.

2025-01 2025-06: $125,453 bought 2025-06: $4.10M sold 2025-07 2025-08: $673,714 sold 2026-01 2026-05: $7.06M sold 2026-06: $1.62M sold 2026-07: $5.83M sold 2026-07 2026-08: $10.67M sold 2026-10: $229,406 sold
Bought Sold Largest month: $10.67M

Who traded, two years

InsiderBoughtSold TradesLast tradeHolds after
Brynjelsen SeanDirector, President & CEO – $13.51M 11 2026-08-20 1,004,909
Opaleye Management Inc.10% owner $205,253 $5.83M 10 2026-07-14 –
Krempa DavidChief Business Officer – $5.59M 10 2026-10-06 43,381
Maier Paul VDirector – $2.95M 3 2026-08-28 73,358
Adams Jennifer McKieDirector – $1.62M 1 2026-06-17 0
Gruber James R.Chief Financial Officer – $673,714 2 2025-08-20 204,753

Open-market purchases and sales

Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.

DateInsiderTradeShares PriceValueHolds afterFiling
2026-10-06 Krempa DavidChief Business Officer Sale 4,166 55.07 $229,406 43,381 Form 4
2026-08-28 Maier Paul VDirector Sale 36,387 58.64 $2.13M 73,358 Form 4/A
2026-08-28 Maier Paul VDirector Sale 13,485 60.21 $811,932 59,873 Form 4/A
2026-08-28 Maier Paul VDirector Sale 128 61.77 $7,907 59,745 Form 4/A
2026-08-24 Krempa DavidChief Business Officer Sale 25,000 65.07 $1.63M 37,025 Form 4
2026-08-20 Brynjelsen SeanDirector, President & CEO Sale 47,307 60.17 $2.85M 1,004,909 Form 4
2026-08-20 Brynjelsen SeanDirector, President & CEO Sale 36,373 61.11 $2.22M 968,536 Form 4
2026-08-20 Brynjelsen SeanDirector, President & CEO Sale 7,342 62.12 $456,085 961,194 Form 4
2026-08-19 Brynjelsen SeanDirector, President & CEO Sale 8,978 62.65 $562,472 1,052,216 Form 4
2026-07-14 Opaleye Management Inc.10% owner Saleindirect 15,000 37.54 $563,100 2,665,000 Form 4/A
2026-07-14 Opaleye Management Inc.10% owner Saleindirect 13,315 37.54 $499,845 40,000 Form 4/A
2026-07-07 Opaleye Management Inc.10% owner Saleindirect 20,000 38.37 $767,400 2,680,000 Form 4
2026-07-07 Opaleye Management Inc.10% owner Saleindirect 6,685 38.37 $256,503 53,315 Form 4
2026-07-06 Opaleye Management Inc.10% owner Saleindirect 10,000 38.00 $380,000 2,700,000 Form 4
2026-07-02 Opaleye Management Inc.10% owner Saleindirect 65,000 37.39 $2.43M 2,710,000 Form 4
2026-07-02 Opaleye Management Inc.10% owner Saleindirect 25,000 37.39 $934,750 60,000 Form 4
2026-06-17 Adams Jennifer McKieDirector Sale 50,000 32.48 $1.62M 0 Form 4
2026-05-28 Brynjelsen SeanDirector, President & CEO Sale 119,852 31.88 $3.82M 833,842 Form 4
2026-05-28 Brynjelsen SeanDirector, President & CEO Sale 148 32.67 $4,835 833,694 Form 4
2026-05-27 Krempa DavidChief Business Officer Sale 19,679 31.47 $619,298 25,249 Form 4
2026-05-26 Krempa DavidChief Business Officer Sale 37,524 31.49 $1.18M 25,249 Form 4
2026-05-22 Krempa DavidChief Business Officer Sale 32,963 33.22 $1.10M 35,083 Form 4
2026-05-22 Krempa DavidChief Business Officer Sale 9,315 33.88 $315,592 25,768 Form 4
2026-05-22 Krempa DavidChief Business Officer Sale 519 35.00 $18,165 25,249 Form 4
2025-08-20 Gruber James R.Chief Financial Officer Sale 2,631 16.02 $42,149 204,753 Form 4
2025-08-19 Gruber James R.Chief Financial Officer Sale 39,082 16.16 $631,565 205,299 Form 4
2025-06-16 Krempa DavidChief Business Officer Sale 10,223 14.73 $150,585 612,646 Form 4
2025-06-13 Krempa DavidChief Business Officer Sale 6,800 14.77 $100,436 622,869 Form 4
2025-06-12 Krempa DavidChief Business Officer Sale 16,977 14.92 $253,297 629,669 Form 4
2025-06-10 Opaleye Management Inc.10% owner Buyindirect 5,000 15.82 $79,100 2,770,000 Form 4
2025-06-10 Opaleye Management Inc.10% owner Buyindirect 2,930 15.82 $46,353 85,000 Form 4
2025-06-05 Brynjelsen SeanDirector, President & CEO, 10% owner Sale 70,000 16.81 $1.18M 2,873,513 Form 4
2025-06-04 Brynjelsen SeanDirector, President & CEO, 10% owner Sale 70,000 17.00 $1.19M 2,943,513 Form 4
2025-06-03 Brynjelsen SeanDirector, President & CEO, 10% owner Sale 60,945 17.38 $1.06M 3,022,568 Form 4
2025-06-03 Brynjelsen SeanDirector, President & CEO, 10% owner Sale 8,655 18.38 $159,079 3,013,913 Form 4
2025-06-03 Brynjelsen SeanDirector, President & CEO, 10% owner Sale 400 19.02 $7,608 3,013,513 Form 4
2024-10-23 Opaleye Management Inc.10% owner Buyindirect 10,000 7.98 $79,800 2,770,000 Form 4

Grants, exercises and other transactions

Pay, tax and paperwork rather than a choice to trade at the market price. Two years.

18 × option exercise7 × shares withheld for tax1 × option exercise
Show them
DateInsiderWhatShares PriceHolds afterFiling
2026-10-02 Krempa DavidChief Business Officer Option exercise M +10,522 – 47,547 Form 4
2026-08-28 Maier Paul VDirector Option exercise M +50,000 3.78 109,745 Form 4/A
2026-08-28 Maier Paul VDirector Option exercise M +12,500 7.31 72,245 Form 4/A
2026-08-24 Krempa DavidChief Business Officer Option exercise M +25,000 7.31 62,025 Form 4
2026-07-14 Brynjelsen SeanDirector, President & CEO Option exercise M +200,000 1.37 1,061,194 Form 4
2026-07-12 Brynjelsen SeanDirector, President & CEO Option exercise M +27,500 – 861,194 Form 4
2026-07-12 Krempa DavidChief Business Officer Option exercise M +10,000 – 37,025 Form 4
2026-06-17 Adams Jennifer McKieDirector Option exercise M +50,000 3.78 50,000 Form 4
2026-05-27 Krempa DavidChief Business Officer Option exercise M +12,476 1.37 37,725 Form 4
2026-05-27 Krempa DavidChief Business Officer Option exercise M +7,203 3.58 44,928 Form 4
2026-05-26 Krempa DavidChief Business Officer Option exercise M +25,000 1.38 50,249 Form 4
2026-05-26 Krempa DavidChief Business Officer Option exercise M +12,524 1.37 62,773 Form 4
2026-05-22 Krempa DavidChief Business Officer Option exercise M +30,591 3.58 68,046 Form 4
2026-04-21 Riedel Norbert GDirector Option exercise M +12,500 7.31 47,500 Form 4
2026-04-21 Riedel Norbert GDirector Option exercise M +19,655 8.61 67,155 Form 4
2026-02-03 Riedel Norbert GDirector Option exercise X +30,000 4.42 35,000 Form 4
2026-01-14 Gruber James R.Chief Financial Officer Shares withheld for tax F −2,293 15.47 213,420 Form 4
2026-01-14 Krempa DavidChief Business Officer Shares withheld for tax F −1,942 15.62 630,238 Form 4
2026-01-01 Brynjelsen SeanDirector, President & CEO, 10% owner Shares withheld for tax F −5,015 15.39 2,889,266 Form 4
2025-12-12 Brynjelsen SeanDirector, President & CEO, 10% owner Shares withheld for tax F −6,732 16.83 2,894,281 Form 4
2025-12-12 Gruber James R.Chief Financial Officer Shares withheld for tax F −4,542 16.99 215,713 Form 4
2025-12-12 Krempa DavidChief Business Officer Shares withheld for tax F −6,264 17.00 632,180 Form 4
2025-12-12 Erdogan-Trinkaus IpekChief Commercial Officer Shares withheld for tax F −85 16.90 2,403 Form 4
2025-01-03 Riedel Norbert GDirector Option exercise M +27,400 3.58 87,145 Form 4
2025-01-03 Riedel Norbert GDirector Option exercise M +50,000 3.78 137,145 Form 4
2025-01-03 Riedel Norbert GDirector Option exercise M +25,000 3.47 162,145 Form 4

How to read it

Buy, sale
Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
Plan
A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
Holds after
The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
Value
Shares times the price the form reports, which is often an average over several fills on the day.

Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.

Eton Pharmaceuticals's scores and multiples ›